Pricing

Zofran Lawsuit Update: Plaintiffs Question Why GSK Hasn’t Faced Stiffer Penalties

Download as PDF Single Release RSS Feed
Facebook Twitter Reddit LinkedIn Email

ZofranLegal.com reports that, as plaintiffs learn more about the defendant named in the more than 230 lawsuits, they are beginning to question why the company hasn’t suffered harsher penalties in the past.

These plaintiffs are all alleging that an unborn child developed a birth defect after the mother was prescribed the anti-nausea medication Zofran as a treatment for morning sickness. They also claim that GlaxoSmithKline, the makers of the drug, marketed the drug unlawfully for “off-label” use, failed to inform the medical community of potential side effects, and didn’t perform the necessary safety testing before informing doctors and the public that Zofran was “safe” for pregnant women.

The drug has been available via prescription since 1991. While the U.S. Food and Drug Administration did approve the drug, their label indicates that it should be given to patients who are suffering from nausea and vomiting after undergoing treatments involving chemotherapy, radiation, and anesthesia. The FDA did not approve the drug as a treatment for morning sickness.

Plaintiffs are claiming that the drug caused cleft lip, cleft palate, atrial septal defect, ventricular septal defect, respiratory distress syndrome, ear deformities, and kidney defects.

This isn’t the first time the company has faced a lawsuit regarding one of its drugs. Between the years of 1991 and 2005, the company has paid nearly $8 billion dollars in settlements to the federal government. While this number may seem very high, it pales in comparison to the amount the company has made in profits off of their products. Many have wondered if higher amounts in settlement payments would prevent the company from making decisions which could potentially cause thousands of people harm.

The attorneys at Monheit Law are currently offering complimentary consultations to anyone who believes their unborn child developed a birth defect due to Zofran. For more information, contact Michael Monheit at 877-620-8411.

Download as PDF Single Release RSS Feed
Facebook Twitter Reddit LinkedIn Email

About ZofranLegal.com :

Sponsored by an alliance of attorneys, ZofranLegal.com is a resource for parents, families and birth defect survivors interested in learning more about litigation surrounding the nausea drug Zofran and its link to increased risks of major birth defects.

Contact ZofranLegal.com:

Michael Monheit

1368 Barrowdale Road, Rydal, PA 19046

1-877-620-8411

Social Media:

Additional News Releases From ZofranLegal.com:

April 30, 2016Lawsuit Alleges Invokana Side Effects Can Include Diabetic Ketoacidosis, a Life-Threatening Condition Related to Too Much Acid in the Body

April 29, 2016Zofran Lawsuit Update: Plaintiffs Question Why GSK Hasn’t Faced Stiffer Penalties

April 27, 2016Arkansas Mother Files Zofran Lawsuit Claiming Multiple Defects Caused By Drug

April 25, 2016Zofran Lawsuit Plaintiffs Applaud FDA’s Decision Regarding Folic Acid

April 22, 2016MyFoxBoston News Release Discusses Concerning Zofran Birth Defect Lawsuits And Drug Safety

April 22, 2016Zofran Lawsuit Plaintiffs Note Results Of Japanese Animal Studies Linking Birth Defects To Drug

April 22, 2016A Look Back At America’s First Zofran Lawsuit

April 21, 2016Significant Increase In Birth Defect Development Investigated By Washington State Amid Mounting Zofran Lawsuits

April 21, 2016Zofran Lawsuit Plaintiffs Make Note Of Canadian Label Differences On Drug Which Warn Of Use During Pregnancy

April 20, 2016Zofran Lawsuit Plaintiff Claims Infant’s Cleft Palate, Clubfoot, And Respiratory Distress Caused By Drug Exposure